Latest Conference Articles

November 22nd 2015, 11:27am

SMR Congress

A treatment regimen of pembrolizumab plus low-dose ipilimumab was tolerable and effective for patients with advanced melanoma.

November 22nd 2015, 10:30am

Society for Neuro-Oncology Annual Meeting

The deployment of precision medicine to develop safe and effective therapies to treat malignant brain tumors is an effort that poses both opportunities and challenges.

November 22nd 2015, 9:57am

Society for Neuro-Oncology Annual Meeting

An international coalition of experts is planning an innovative clinical trial aimed at speeding up the development of new treatments for patients with glioblastoma multiforme, putting into motion a biomarker-driven approach that has been employed in other malignancies.

November 22nd 2015, 9:15am

Society for Neuro-Oncology Annual Meeting

Hideho Okada MD, PhD, discusses the need for a new immunotherapy response assessment in euro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

November 22nd 2015, 9:01am

Society for Neuro-Oncology Annual Meeting

Nicholas A. Butowski, MD, discusses an early-stage study of convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.

November 22nd 2015, 8:15am

Society for Neuro-Oncology Annual Meeting

A pilot study of the efficacy of CAR T-cell therapy in patients with EGFRvIII-positive glioblastoma multiforme (GBM) has generated encouraging findings.

November 22nd 2015, 7:17am

SMR Congress

In the largest-to-date analysis of treatment-naïve metastatic melanoma patients with BRAF V600 mutations treated with dabrafenib and trametinib, researchers have found that baseline LDH levels and number of disease sites were the most significant factors affecting survival.

November 21st 2015, 4:11pm

SMR Congress

Two separate early phase clinical trials exploring pembrolizumab-containing immunotherapy combinations have shown objective response rates over 50% in patients with advanced melanoma.

November 21st 2015, 2:01pm

Society for Neuro-Oncology Annual Meeting

Maciej M. Mrugala, MD, PhD, discusses a retrospective analysis looking at adding cycles of treatment with temozolomide in newly diagnosed patients with glioblastoma.

November 21st 2015, 1:52pm

Society for Neuro-Oncology Annual Meeting

Treatment with the immunotherapy rindopepimut plus bevacizumab resulted in a 47% reduction in the risk of death compared with bevacizumab and a control for patients with relapsed glioblastoma multiforme.

November 21st 2015, 12:58pm

Society for Neuro-Oncology Annual Meeting

Amy B. Heimberger, MD, discusses the potential of FGL2 as a multi-modality regulator of tumor-mediated immune suppression in patients with glioblastoma.

November 21st 2015, 12:12pm

SMR Congress

Making real strides in melanoma care requires an understanding of BRAF resistance mechanisms.

November 21st 2015, 10:38am

Society for Neuro-Oncology Annual Meeting

Findings from a subgroup of patients enrolled in a phase II study assessing the dendritic vaccine ICT-107 for patients with HLA-A2+ glioblastoma multiforme merit further exploration in a phase III study.

November 21st 2015, 10:02am

SMR Congress

Georgina Long, BSc, PhD, MBBS, FRACP, medical oncologist, translational researcher, Melanoma Institute Australia, The University of Sydney, discusses which patients may benefit from the combination of dabrafenib and trametinib based on several recent clinical trials.

November 21st 2015, 9:46am

Society for Neuro-Oncology Annual Meeting

Though clinical work is ongoing and early, researchers are already considering how to manage potentially fatal neurotoxicities in patients treated with chimeric antigen receptor T-cell therapy

November 21st 2015, 8:48am

SMR Congress

Victoria Atkinson, MD, of Princess Alexandra Hospital and Gallipoli Medical Research Foundation, Queensland, discusses long-term data from the phase III CheckMate-066 trial.

November 20th 2015, 3:41pm

SMR Congress

Since the approval of the first checkpoint inhibitor, ipilimumab, several combinations and monotherapies have gained rapid approval, with continued expansion on the horizon.

November 20th 2015, 3:28pm

Society for Neuro-Oncology Annual Meeting

John H. Sampson, MD, PhD, MBA, MHSc, discusses results from cohort 1 of the CHECKMATE-143 trial.

November 20th 2015, 3:06pm

Society for Neuro-Oncology Annual Meeting

There are reasons to suggest that immune checkpoint inhibitors may be successful against central nervous system tumors, including glioblastoma.

November 20th 2015, 2:28pm

Society for Neuro-Oncology Annual Meeting

The addition of Optune to chemotherapy and/or bevacizumab improved survival in patients with recurrent glioblastoma multiforme.